Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Jun 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/ …